Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Robinson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
BMC Public Health|March 15, 2019
Engaging parents using web-based feedback on child growth to reduce childhood obesity: a mixed methods studyRinita Dam, Heather Anne Robinson, Sarah Vince-Cain, et al.
The American Surgeon|May 3, 2025
A Model for Use of Low-Titer "O" Whole Blood in a Community Level III Trauma Center: Cost Effectiveness, Utilization, and Prevention of Precious Resource WastageCharles D Mabry, J R Taylor, Kaylee Velasquez, et al.
Frontiers in Neuroimaging|August 9, 2023
Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studiesEmily Anne Robinson, John Gleeson, Arush Honnedevasthana Arun, et al.
Histopathology|May 19, 2011
Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipientsKatarzyna Anna Mackenzie, Andrew Peter Miller, Barry David Hock, et al.
BMC Cancer|October 3, 2014
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyChristopher G C A Jackson, Katrina Sharples, Paul I Thompson, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Leukemia|December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hitFrancesco Cucco, Sharon Barrans, Chulin Sha, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2011
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015), Rajiv K Agrawal, Abdulla Alhasso, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
BMC Public Health|March 15, 2019
Engaging parents using web-based feedback on child growth to reduce childhood obesity: a mixed methods studyRinita Dam, Heather Anne Robinson, Sarah Vince-Cain, et al.
The American Surgeon|May 3, 2025
A Model for Use of Low-Titer "O" Whole Blood in a Community Level III Trauma Center: Cost Effectiveness, Utilization, and Prevention of Precious Resource WastageCharles D Mabry, J R Taylor, Kaylee Velasquez, et al.
Frontiers in Neuroimaging|August 9, 2023
Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studiesEmily Anne Robinson, John Gleeson, Arush Honnedevasthana Arun, et al.
Histopathology|May 19, 2011
Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipientsKatarzyna Anna Mackenzie, Andrew Peter Miller, Barry David Hock, et al.
BMC Cancer|October 3, 2014
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyChristopher G C A Jackson, Katrina Sharples, Paul I Thompson, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Leukemia|December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hitFrancesco Cucco, Sharon Barrans, Chulin Sha, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2011
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015), Rajiv K Agrawal, Abdulla Alhasso, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Pageof 2